Emmes, a global, full-service clinical research organization committed to supporting healthcare advancement and biopharmaceutical innovation, announces the acquisition of VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS employs more than 160 employees to manage and monitor vaccine clinical trials throughout Latin America.
“Clinical research today is more complex and more global in nature than ever before,” said Emmes Executive Chairman Sastry Chilukuri . “Combining VaxTRIALS’ deep expertise and experience in Latin America with Emmes’ capabilities, particularly in technology, biostatistics and data management, will provide clients with an unrivaled level of partnership in the conduct of their clinical trials.”
“VaxTRIALS is a perfect complement to Emmes’ capabilities,” said Emmes CEO Peter Ronco. “It expands our global reach, adding to North America, Europe and Asia, where we already operate, Latin America is one of the fastest growing regions for clinical research, driven by its large and diverse patient population and high-quality clinical trial sites.” VaxTRIALS brings us a number of new clients from biopharmaceutical companies and public-private partnerships, further strengthening one of our strongest areas of therapeutic research: vaccines and infectious diseases.”
VaxTRIALS’ vaccine-related clinical trials were conducted in 11 Latin American countries, as well as the Philippines.
Also Read : Hackensack Meridian Health Research Institute Creates First Spin-off Company, EValuate Diagnostics
VaxTRIALS staff have provided support for clinical trials aimed at preventing diseases such as influenza, dengue fever, chikungunya, hepatitis A, meningitis, norovirus, herpes zoster, whooping cough, respiratory syncytial virus (RSV), polio, and COVID-19.
“Another advantage for Emmes,” continued Mr. Ronco, “is that we will be able to leverage VaxTRIALS’ established network in Latin America to recruit clinical trial participants in our other core therapeutic research areas, including rare and pediatric diseases, cell and gene therapy and ophthalmology.”
“Both of our companies have built strong customer relationships and a distinct heritage in vaccine and infectious disease research,” said VaxTRIALS CEO Dr. José Jimeno. “I am proud that we have made people and culture a priority, including hiring and developing employees who are deeply committed to making positive changes in health care.”
“I also look forward to bringing Emmes‘ technology expertise and deep expertise in biostatistical analysis and data management to the benefit of our clients throughout Latin America,” he added. “The Emmes Advantage eClinical data management platform, which provides benefits such as improved data quality, simplified oversight of clinical trial operations, and reduced clinical trial timelines and costs, can be extremely beneficial to our clients.”
Mr. Chilukuri noted, “José Gimeno combines his training and experience as a physician with extensive knowledge of the industry and the Latin American region, as well as an outstanding reputation in the global vaccine development community. As founder and CEO of VaxTRIALS, he has proven to be an extremely active and energetic leader. We are very pleased to welcome Jose and the VaxTRIALS team to Emmes.”
SOURCE : PRNewswire